Stocks Screener

Specify Company / Ticker to Get the Summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Dividend History ANIK

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Dividend Analytics ANIK

Max Ratio

5Y Dividend Growth

Consecutive Years

5Y Average Payout Ratio

Forward Annual Dividend Yield
Consecutive Years
Forward Annual Dividend – USD
Consistent Years
Dividend CAGR 3Y
Continuous Dividends
Dividend CAGR 5Y
Payout Ratio TTM
Dividend CAGR 10Y
Ex Dividend Date

Anika Therapeutics Inc

ANIK
Current price
10.92 USD +0.28 USD (+2.63%)
Last closed 10.59 USD
ISIN US0352551081
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
Exchange NASDAQ
Capitalization 159 189 552 USD
Yield for 12 month -57.87 %
1Y
3Y
5Y
10Y
15Y
ANIK
21.11.2021 - 28.11.2021

Anika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and arthrosurface joint solutions in the United States, Europe, and internationally. The company develops, manufactures, and commercializes products based on hyaluronic acid (HA) technology platform. Its OA pain management products include Monovisc and Orthovisc, an injectable HA-based viscosupplement for the pain relief from osteoarthritis conditions; and Cingal, a single-injection OA pain management product to provide short-and long-term pain relief. The company's joint preservation and restoration product family comprises orthopedic regenerative solutions, including Hyalofast and Tactoset; sports medicine solutions to repair and reconstruct damaged ligaments and tendons; and preserving joint solutions, including partial joint replacement, joint resurfacing, and invasive and bone sparing implants to treat upper and lower extremity orthopedic conditions. In addition, the company offers non-orthopedic products comprising HA-based products for Hyvisc, a molecular weight injectable HA veterinary product; Hyalobarrier, an anti-adhesion barrier for use after abdominal-pelvic surgeries; and Hyalomatrix for the treatment of burns and ulcers, as well as products used for the treatment of ears, nose and throat disorders, and ophthalmic. Anika Therapeutics, Inc. was founded in 1983 and is headquartered in Bedford, Massachusetts. Address: 32 Wiggins Avenue, Bedford, MA, United States, 01730

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

21.33 USD

P/E ratio

Dividend Yield

Financials ANIK

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Key Figures ANIK

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Current Year

+119 907 000 USD

Last Year

+166 662 000 USD

Current Quarter

+26 168 000 USD

Last Quarter

-1 290 000 USD

Current Year

+75 998 000 USD

Last Year

+103 088 000 USD

Current Quarter

+14 681 000 USD

Last Quarter

+22 565 000 USD
EBITDA 1 376 000 USD
Operating Margin TTM -16.37 %
Price to Earnings
Return On Assets TTM -1.73 %
PEG Ratio 1.91
Return On Equity TTM -6.07 %
Wall Street Target Price 21.33 USD
Revenue TTM 117 053 000 USD
Book Value 10.35 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY -9.80 %
Dividend Yield
Gross Profit TTM 72 310 000 USD
Earnings per share -0.75 USD
Diluted Eps TTM -0.75 USD
Most Recent Quarter I 2025
Quarterly Earnings Growth YOY -50.50 %
Profit Margin -48.48 %

Stock Valuation ANIK

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE 19.12
Enterprise Value Revenue 1.12
Price Sales TTM 1.36
Enterprise Value EBITDA 170.46
Price Book MRQ 1.07

Technical indicators ANIK

For 52 weeks

10.55 USD 29.12 USD
50 Day MA 12.67 USD
Shares Short Prior Month 407 027
200 Day MA 17.45 USD
Short Ratio 5.40
Shares Short 412 969
Short Percent 3.38 %